Dna-based aptamers for human cathepsin g
AssigneeGentium S.R.L.
InventorsManlio PALUMBO, Barbara GATTO, Rodolfo PESCADOR, Roberto PORTA, Laura Iris FERRO
Life of this patent
Estimating the term…
Abstract
The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing.
Claims15
A method for the treatment and prophylaxis of a disease selected from the group consisting of inflammatory occurrences, procoagulant conditions, genetic diseases, degenerative diseases, DNA damages, neoplasia and skin diseases, which comprises administering to a patient cathepsin G-inhibiting aptamers consisting of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and undergoing inter and/or intra molecular base pairing to an extent lower than 20%, said sequences being characterized by:
- having a molar ratio AG/TC of 1.0÷2.0;
- or
- being (GT)n or (AC)n oligopolymers in which n is higher than 30;
- or
- being (T)n or (G)n or (A)n or (C)n or (Inosine)n omopolymers in which n is higher than 60.
Dependencies are inferred from the claim text.